全文获取类型
收费全文 | 70625篇 |
免费 | 5093篇 |
国内免费 | 2473篇 |
专业分类
耳鼻咽喉 | 318篇 |
儿科学 | 971篇 |
妇产科学 | 1252篇 |
基础医学 | 11827篇 |
口腔科学 | 960篇 |
临床医学 | 3868篇 |
内科学 | 11155篇 |
皮肤病学 | 1096篇 |
神经病学 | 10327篇 |
特种医学 | 839篇 |
外国民族医学 | 19篇 |
外科学 | 4256篇 |
综合类 | 7557篇 |
现状与发展 | 7篇 |
预防医学 | 1610篇 |
眼科学 | 625篇 |
药学 | 13942篇 |
5篇 | |
中国医学 | 1513篇 |
肿瘤学 | 6044篇 |
出版年
2024年 | 45篇 |
2023年 | 777篇 |
2022年 | 1052篇 |
2021年 | 1950篇 |
2020年 | 1802篇 |
2019年 | 1852篇 |
2018年 | 1948篇 |
2017年 | 1963篇 |
2016年 | 2016篇 |
2015年 | 2338篇 |
2014年 | 3878篇 |
2013年 | 5330篇 |
2012年 | 3831篇 |
2011年 | 4507篇 |
2010年 | 3693篇 |
2009年 | 3801篇 |
2008年 | 4127篇 |
2007年 | 3724篇 |
2006年 | 3249篇 |
2005年 | 2814篇 |
2004年 | 2650篇 |
2003年 | 2446篇 |
2002年 | 1961篇 |
2001年 | 1711篇 |
2000年 | 1556篇 |
1999年 | 1338篇 |
1998年 | 1373篇 |
1997年 | 1318篇 |
1996年 | 1144篇 |
1995年 | 1074篇 |
1994年 | 975篇 |
1993年 | 897篇 |
1992年 | 688篇 |
1991年 | 613篇 |
1990年 | 480篇 |
1989年 | 399篇 |
1988年 | 342篇 |
1987年 | 317篇 |
1986年 | 346篇 |
1985年 | 402篇 |
1984年 | 320篇 |
1983年 | 212篇 |
1982年 | 270篇 |
1981年 | 202篇 |
1980年 | 142篇 |
1979年 | 94篇 |
1978年 | 64篇 |
1977年 | 49篇 |
1976年 | 40篇 |
1975年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
Shahid Ahmed MD PhD FRCPC Sukanya Pati MD Duc Le MD MSc FRCPC Kamal Haider MD Nayyar Iqbal MD FRCP 《Journal of surgical oncology》2020,122(2):144-154
Over the past two decades, gene expression profiling of breast cancer has emerged as an important tool in early-stage breast cancer management. The approach provides important information on underlying biological mechanisms, breast cancer classification, future risk potential of developing recurrent metastatic disease, and provides beneficial clues for adjuvant chemotherapy in hormone receptor (HR) positive breast cancer. Of the commercially available genomic tests for breast cancer, the prognostic and predictive value of 21-gene recurrence score tests have been validated using both retrospective data and prospective clinical trials. In this paper, we reviewed the current evidence on 21-gene expression profiles for HR-positive HER2-negative early-stage breast cancer management. We show that current evidence supports endocrine therapy alone as an appropriate adjuvant systemic therapy for approximately 70% of women with HR-positive, HER2-negative, node-negative breast cancer. Evolving evidence also suggests that 21-gene recurrence scores have predictive values for node-positive breast cancer and that chemotherapy can be avoided in more than half of women with nodes 1 to 3 positive HR-positive breast cancer. Furthermore, retrospective data also supports the predictive role of 21-gene recurrence scores for adjuvant radiation therapy. A prospective trial in this area is ongoing. 相似文献
43.
44.
Min Hee Hong MD Seong Gu Heo PhD Yun-Gyoo Lee MD PhD Hyo Song Kim MD PhD Keon Uk Park MD PhD Hoon-Gu Kim MD PhD Yoon Ho Ko MD PhD Ik-Joo Chung MD PhD Young Joo Min MD PhD Min Kyoung Kim MD PhD Kyu Ryung Kim PhD Jinseon Yoo MS Tae-Min Kim MD PhD Hye Ryun Kim MD PhD Byoung Chul Cho MD PhD 《Cancer》2020,126(20):4521-4531
45.
46.
ObjectiveDiabetic kidney disease (DKD) is the leading cause of death and disability of diabetes mellitus. However, there is still a lack of specific drugs for the treatment of DKD. The chief aim of this research is to investigate the role and mechanism of 2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione (DMDD) for DKD.MethodsWild type and TLR4 knockout mice were induced to diabetes. After 4-week treatment with DMDD, blood sugar, renal function, blood lipid and pathological changes were assessed. Real-time PCR, western blotting, and immunohistochemistry were employed to detect the expressions of TLR4, TGFβ1 and Smad2/3 in the renal tissue.ResultsDMDD improved the serum lipid and decreased fasting blood glucose levels in diabetic mice. CysC and urinary albumin levels increased markedly in the diabetic group, and they were obviously decreased after 4 weeks of DMDD treatment. Compared with the WT diabetic mice, the urinary albumin and CysC in the TLR4-/- mice were expressed at lower levels. HE and Masson’s staining revealed that DMDD clearly ameliorated pathological changes and renal fibrosis. When TLR4 gene was knock out, the pathological was improved. Mechanistically, TLR4, TGF-β1 and Smad2/3 were obvious up-regulation in the renal tissues of diabetic mice. The expressions of these proteins were significantly down-regulated after DMDD treatment (p < 0.05). In the TLR4-/- mice, mRNA and protein levels of TGF-β1 and Smad2/3 were obviously lower than those in the WT mice. In addition, IHC revealed that a strong in situ expressions of TLR4, TGF-β1 and Smad2/3 were seen in the kidney tissues of diabetic mice, which were distinctly weakened in the DMDD-treated mice. In the TLR4-/- mice, however, expressions of TGF-β1 and Smad2/3 were not remarkable increase in the diabetic mice compared with normal mice.ConclusionsThese results strongly indicate that TLR4 is essential for DMDD protection against renal dysfunction in diabetic mice. Its hypoglycemic and anti-fibrosis effects were likely mediated by the TLR4/TGFβ signaling pathway. 相似文献
47.
The Chinese herbal medicine oridonin has potent anti-inflammatory and antitumor activities. In addition, oridonin treatment effectively suppresses breast cancer growth. However, the underlying mechanisms are poorly defined. Here, we reported that oridonin decreased Treg differentiation in vitro and in vivo. Oridonin inhibition of Treg differentiation was dependent on decreasing TGF-β receptor expression. Oridonin attenuated Tregs’ immunosuppressive ability; thus, oridonin did not inhibit CD8+ T cell proliferation very well in vitro. Oridonin greatly delayed the progression of 4T1 tumors in vivo. In addition, oridonin combined with anti-PD-1 activated a robust antitumor immune response and suppressed 4T1 tumor growth. Therefore, our results indicate that oridonin inhibits TNBC growth by modulating Treg differentiation, which provides new directions for the clinical treatment of TNBC. 相似文献
48.
49.
B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoting T cell response, and killing cancer cells directly. Given these properties, their anti-tumor immune response in the tumor micro-environment (TME) is of great interest. Although T cell-related immune responses have become a therapeutic target with the introduction of immune checkpoint inhibitors, not all patients benefit from these treatments. B cell and B cell-related pathways (CCL19, −21/CCR7 axis and CXCL13/CXCR5 axis) play key roles in activating immune response through humoral immunity and local immune activation via tertiary lymphoid structure (TLS) formation. However they have some protumorigenic works in the TME. Thus, a better understanding of B cell and B cell-related pathways is necessary to develop effective cancer control. In this review, we summarize recent evidences regarding the roles of B cell and B cell-related pathways in the TME and immune response and discuss their potential roles for novel cancer treatment strategies. 相似文献
50.